Geneva, May 20 -- International Clinical Trials Registry received information related to the study (NCT06962280) titled 'A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight' on May 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Eli Lilly and Company
Condition:
Type 1 Diabetes
Obesity
Overweight
Intervention:
Drug: Tirzepatide
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: May 2025
Target Sample Size: 465
Countries of Recruitment:
United States
Argentina
Brazil
Canada
Czechia
France
Greece
Mexico...